Applied Therapeutics, Inc.
APLT
$0.3987
$0.00040.10%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 100.00% | -- | -- | -98.22% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 100.00% | -- | -- | -98.22% | -- |
| Cost of Revenue | -23.58% | 37.49% | -15.81% | -23.33% | -72.49% |
| Gross Profit | 26.77% | -36.36% | 17.02% | -128.00% | 71.29% |
| SG&A Expenses | 323.32% | 219.26% | 99.89% | 62.39% | -26.77% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 62.34% | 92.74% | 19.84% | -1.09% | 7.22% |
| Operating Income | -57.19% | -91.95% | -19.00% | -94.26% | -10.73% |
| Income Before Tax | 216.79% | -61.89% | 109.80% | -728.04% | -161.13% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 216.79% | -61.89% | 109.80% | -728.04% | -161.13% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 216.79% | -61.89% | 109.80% | -728.04% | -161.13% |
| EBIT | -57.19% | -91.95% | -19.00% | -94.26% | -10.73% |
| EBITDA | -57.19% | -91.95% | -19.01% | -94.26% | -10.74% |
| EPS Basic | 189.35% | -1.69% | 105.37% | -272.32% | -18.00% |
| Normalized Basic EPS | 189.52% | -1.64% | 105.43% | -272.42% | -17.64% |
| EPS Diluted | 188.50% | -1.69% | 65.21% | -272.22% | -18.00% |
| Normalized Diluted EPS | 189.52% | -1.64% | 105.13% | -272.42% | -17.64% |
| Average Basic Shares Outstanding | 30.70% | 59.20% | 82.10% | 122.36% | 121.30% |
| Average Diluted Shares Outstanding | 30.70% | 59.20% | 92.80% | 122.36% | 121.30% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |